Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant

Eur Respir J. 2018 May 3;51(5):1702330. doi: 10.1183/13993003.02330-2017. Print 2018 May.

Authors

Takashi Hirama^{1

2

3}, Sarah K Brode^{1

2

3}, Jenifer Beswick¹, Arjun D Law⁴, Wilson Lam⁴, Fotios V Michelis⁴, Santhosh Thyagu⁴, Auro Viswabandya⁴, Jeffrey H Lipton⁴, Hans A Messner⁴, Dennis Dong Hwan Kim^{1

4}, Theodore K Marras^{1

3}

Affiliations

¹ Division of Respirology, Dept of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Respirology, Dept of Medicine, Toronto Western Hospital, Toronto, ON, Canada.
³ Dept of Respiratory Medicine, West Park Healthcare Center, Toronto, ON, Canada.
⁴ Allogeneic Blood and Marrow Transplant Program, Dept of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

PMID: 29545280
DOI: 10.1183/13993003.02330-2017

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-Bacterial Agents / therapeutic use*
Female
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Male
Middle Aged
Mycobacterium Infections, Nontuberculous / drug therapy*
Mycobacterium Infections, Nontuberculous / epidemiology*
Nontuberculous Mycobacteria / isolation & purification*
Retrospective Studies
Treatment Outcome

Substances

Anti-Bacterial Agents